Frontiers in Diabetic Macular Edema: Durable Suppression for Addressing Health Disparities

Frontiers in Diabetic Macular Edema: Durable Suppression for Addressing Health Disparities

Frontiers in Diabetic Macular Edema: Durable Suppression for Addressing Health Disparities

Can we improve outcomes in DME by going beyond VEGF inhibition? Join us to learn about novel targets, their mechanisms, and the latest clinical data.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving upon the durability of VEGF suppression. These new treatments that go beyond the current standard of care may help reduce treatment burdens and ultimately improve vision outcomes in DME. Join our two experts, Dr. Christina Weng and Dr. Arshad Khanani, as they discuss these emerging agents, their mechanisms of action, and the latest available data.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Christina Y. Weng, MD, MBA
    Associate Professor of Ophthalmology
    Fellowship Program Director-Vitreoretinal Diseases & Surgery
    Baylor College of Medicine, Cullen Eye Institute
    Houston, TX 

    Consulting Fees: Alcon, Alimera Sciences, Allergan/AbbVie, D.O.R.C., Genentech, Novartis, Regeneron, REGENXBIO

    Arshad M. Khanani MD, M.A.
    Managing Partner and Director of Clinical Research
    Sierra Eye Associates
    Clinical Associates Professor
    University of Nevada, Reno School of Medicine
    Reno, NV

    Contracted Research: Genentech, Novartis, Oxurion
    Consulting Fees: Genentech, Novartis, Oxurion
    Fees for Non-CME/CE Services Received Directly from Commercial Interest or their Agents: Genentech, Novartis 

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Brian McDonough, MD has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Stephanie Wenick, MPhil, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the mechanism of action of novel DME therapies that address vessel integrity by inhibiting angiopoietin-2 (Ang-2) as well as vascular endothelial growth factor (VEGF)
    • Explain the differences between Ang-1 and Ang-2 inflammation and their manageability
  • Target Audience

    This activity is designed to meet the educational needs of ophthalmic surgeons, ophthalmologists, and retina specialists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free